BioConvergence has forged a 'significant' supply chain partnership with Eli Lilly, worth millions of dollars over ten years.

According to In-Pharma Technologist, the Indiana-based firm will be providing global materials management services for Lilly's pipeline of products. In order to facilitate this, BioConvergence has invested in new equipment and made a 21,000 square foot expansion to its existing facility.

Commenting on the arrangement, Lilly's vice president of Product Research and Development, Bill Heath, said that his company "recognises the growing need to develop fully integrated networks with external partners".

"This deal is part of our ongoing transformation of moving Lilly from a fully integrated pharmaceutical company to a fully integrated pharmaceutical network".

He added that the partnership will allow Lilly to lower the cost of its pipeline's development process by introducing efficiencies within the global supply chain.